Natalizumab

• The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. van Kempen et al., Mult Scler. 2017 May 1:1352458517708464.

 

• Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Caldano et al. Ther Drug Monit. 2017 Aug;39(4):350-355.

 

• Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. van Kempen et al., Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023.

 

• Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. van Schie K et al., J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. 

 

• High cumulative JC virus seroconversion rate during long-term use of natalizumab. Vennegoor et al., Eur J Neurol. 2016 Jun;23(6):1079-85.

 

• High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Harrer et al., Clin Exp Immunol 2015 Jan 20.

 

• Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Vennegoor et al., Mult Scler 2015; 21(4):481-4

 

• Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Vennegoor et al., Mult Scler. 2013 Apr;19(5):593-600

 

• Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Rispens et al., Mult Scler 2012; 18(6):899-901.